1. Home
  2. FICO vs INSM Comparison

FICO vs INSM Comparison

Compare FICO & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Fair Isaac Corproation

FICO

Fair Isaac Corproation

HOLD

Current Price

$954.16

Market Cap

22.3B

ML Signal

HOLD

Logo Insmed Incorporated

INSM

Insmed Incorporated

HOLD

Current Price

$120.26

Market Cap

22.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FICO
INSM
Founded
1956
1988
Country
United States
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
22.3B
22.4B
IPO Year
1995
2000

Fundamental Metrics

Financial Performance
Metric
FICO
INSM
Price
$954.16
$120.26
Analyst Decision
Buy
Strong Buy
Analyst Count
13
24
Target Price
$1,689.92
$201.17
AVG Volume (30 Days)
338.0K
1.7M
Earning Date
04-28-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
29.78
N/A
EPS
28.12
N/A
Revenue
$1,032,475,000.00
N/A
Revenue This Year
$27.28
$182.31
Revenue Next Year
$16.97
$65.19
P/E Ratio
$34.36
N/A
Revenue Growth
N/A
N/A
52 Week Low
$870.01
$90.39
52 Week High
$1,998.01
$212.75

Technical Indicators

Market Signals
Indicator
FICO
INSM
Relative Strength Index (RSI) 35.81 47.19
Support Level $888.00 $119.68
Resistance Level $1,117.39 $130.83
Average True Range (ATR) 40.51 5.04
MACD -5.76 -0.94
Stochastic Oscillator 24.49 24.85

Price Performance

Historical Comparison
FICO
INSM

About FICO Fair Isaac Corproation

Founded in 1956, Fair Isaac Corporation is a leading applied analytics company. Fair Isaac is primarily known for its FICO credit scores, which is a widely used industry benchmark to determine the creditworthiness of an individual consumer. The firm's US-centric credit scores business accounts for most of the firm's revenue and profits and consists of business-to-business and business-to-consumer services. In addition to scores, Fair Isaac also sells software primarily to financial institutions for areas such as analytics, decision-making, customer workflows, and fraud.

About INSM Insmed Incorporated

Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.

Share on Social Networks: